![Joseph Felder](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Joseph Felder
Geen lopende functies
Profiel
Joseph Felder was a Co-Chairman at Crohn's & Colitis Foundation of America.
He was also a Director at Ventrus Biosciences, Inc. from 2008 to 2011.
He holds a doctorate degree from The University of Texas at Austin and another doctorate degree from the University of Texas at San Antonio, which was conferred in 1987.
Eerdere bekende functies van Joseph Felder
Bedrijven | Functie | Einde |
---|---|---|
Crohn's & Colitis Foundation of America
![]() Crohn's & Colitis Foundation of America Miscellaneous Commercial ServicesCommercial Services Crohn's & Colitis Foundation of America is a non-profit organization that is run by volunteers. The non-profit company is based in New York, NY and has subsidiaries in the United States. The organization is dedicated to finding cures for Crohn's disease and ulcerative colitis, and improving the quality of life of children and adults affected by these diseases. The CEO of the company is Richard J. Geswell. | Voorzitter | - |
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | Directeur/Bestuurslid | - |
Opleiding van Joseph Felder
The University of Texas at Austin | Doctorate Degree |
University of Texas at San Antonio | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | Health Technology |
Crohn's & Colitis Foundation of America
![]() Crohn's & Colitis Foundation of America Miscellaneous Commercial ServicesCommercial Services Crohn's & Colitis Foundation of America is a non-profit organization that is run by volunteers. The non-profit company is based in New York, NY and has subsidiaries in the United States. The organization is dedicated to finding cures for Crohn's disease and ulcerative colitis, and improving the quality of life of children and adults affected by these diseases. The CEO of the company is Richard J. Geswell. | Commercial Services |